BriaCell Therapeutics Newsroom

Promising Phase 2 Results and Safety Profile Justify Buy Rating for BriaCell Therapeutics

TipRanksDec 12 06:31 ET

BriaCell Therapeutics Analyst Ratings

BenzingaDec 3 07:42 ET

HC Wainwright & Co. Reiterates Buy on BriaCell Therapeutics, Maintains $15 Price Target

BenzingaDec 3 07:41 ET

BriaCell Therapeutics Analyst Ratings

BenzingaJun 4 06:54 ET

BriaCell Therapeutics Analyst Ratings

BenzingaMay 24 07:24 ET

BriaCell Therapeutics Analyst Ratings

BenzingaDec 28, 2023 11:27 ET

H.C. Wainwright Keeps a Buy Rating on BriaCell Therapeutics (BCT)

TipRanksNov 30, 2023 11:00 ET

BriaCell Therapeutics (BCT) Gets a Buy Rating From H.C. Wainwright

TipRanksOct 27, 2023 06:21 ET

HC Wainwright & Co. Maintains Buy on BriaCell Therapeutics, Lowers Price Target to $20

BenzingaOct 3, 2023 12:03 ET

BriaCell Therapeutics Analyst Ratings

BenzingaOct 3, 2023 12:01 ET

BriaCell Therapeutics (BCT) Initiated With a Buy at H.C. Wainwright

TipRanksOct 3, 2023 11:30 ET

BriaCell Therapeutics (BCT) Initiated With a Buy at H.C. Wainwright

TipRanksSep 8, 2023 12:10 ET

BriaCell Therapeutics (BCT) Gets a Buy Rating From H.C. Wainwright

TipRanksJun 28, 2023 06:20 ET

HC Wainwright & Co. Reiterates Buy on BriaCell Therapeutics, Maintains $25 Price Target

BenzingaJun 28, 2023 06:12 ET

BriaCell Therapeutics Analyst Ratings

BenzingaFeb 24, 2023 06:38 ET